Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TSH BiopharmROCO:8432 89 3-Year RORE % is 36.92 as of Mar. 2026. GuruFocus rates ROCO:8432 with a GF Score™ of 89/100 and a GF Value™ of NT$74.84 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 940 Drug Manufacturers companies, TSH Biopharm ranks better than 78.62% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
TSH Biopharm's 3-Year RORE % for the quarter that ended in Mar. 2026 was 36.92%.
The industry rank for TSH Biopharm's 3-Year RORE % or its related term are showing as below:
ROCO:8432's 3-Year RORE % is ranked better than 78.62% of 940
companies
in the Drug Manufacturers industry
Industry Median: 3.075
vs ROCO:8432: 36.92
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
TSH Biopharm 3-Year RORE % Related Terms
TSH Biopharm 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for TSH Biopharm's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TSH Biopharm 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where TSH Biopharm's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
TSH Biopharm (ROCO:8432) has a 3-Year RORE % of 36.92 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on TSH Biopharm and its competitors. According to the industry distribution chart, TSH Biopharm ranks #201 out of 940 companies in the Drug Manufacturers industry, placing it in the top 21.4%.
Is TSH Biopharm's 3-Year RORE % too high?
TSH Biopharm's current 3-Year RORE % is 36.92. The Drug Manufacturers industry median 3-Year RORE % is 3.08. TSH Biopharm's value of 36.92 is 1100.7% above this industry median. Based on the distribution chart, TSH Biopharm ranks #201 out of 940 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TSH Biopharm has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's 3-Year RORE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TSH Biopharm ranks #201 out of 940 companies for 3-Year RORE %. This places TSH Biopharm in the top 21% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 3.08. TSH Biopharm's value of 36.92 is 1100.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.08, based on 940 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TSH Biopharm's current 3-Year RORE % of 36.92 is 1100.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on TSH Biopharm and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TSH Biopharm's current 3-Year RORE % is 36.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$74.84, compared to a current price of NT$48.80 — trading 34.8% below its estimated fair value. The current 3-Year RORE % is 36.92 and 1100.7% above the Drug Manufacturers industry median of 3.08. TSH Biopharm's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current 3-Year RORE % is 36.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TSH Biopharm (ROCO:8432) Overvalued in 2026?
Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued.
The current stock price of NT$48.80 is trading 34.8% below its estimated GF Value™ of NT$74.84.
GuruFocus considers TSH Biopharm to be Significantly Undervalued.
Key valuation signals for ROCO:8432:
3-Year RORE %: 36.92
GF Value™: NT$74.84 vs. price of NT$48.80 (34.8% below fair value)
Industry Position: 1100.7% above the Drug Manufacturers median (#201 of 940)
No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
89GF Score
Get the complete analysis for ROCO:8432
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8432 has been successfully added to your 
